Does intracoronary verapamil administration improve the 'no-reflow' phenomenon in patients undergoing percutaneous coronary intervention?
Intracoronary verapamil is an effective treatment for the no-reflow phenomenon during percutaneous coronary intervention, suggesting microvascular spasm as a potential etiology.
The no-reflow phenomenon--reduction in distal flow without apparent dissection or distal embolization--occurs in 2% of coronary interventions. It generally responds promptly to intracoronary verapamil administration, suggesting that distal microvascular spasm may be its etiology.
Piana et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: